Affiliation:
1. 3Bio Team CAMB UMR7199 Faculté de Pharmacie CNRS−Université de Strasbourg 74 route du Rhin Illkirch Cedex F‐67401 France
2. Inserm UMR_S 1121 EMR 7003 CNRS Biomaterials and Bioengineering Centre de Recherche en Biomédecine de Strasbourg Université de Strasbourg 1 rue Eugène Boeckel Strasbourg F‐67000 France
3. V‐SAT Team Laboratoire de Conception et Application de Molécules Bioactives UMR 7199 Faculté de Pharmacie CNRS‐Université de Strasbourg Illkirch F‐67401 France
Abstract
AbstractThe physiological problem of chronic inflammation and its associated pathologies attract ongoing attention with regard to methods for their control. Current systemic pharmacological treatments present problematic side effects. Thus, the possibility of new anti‐inflammatory compounds with differing mechanisms of action or biophysical properties is enticing. Cationic polymers, with their ability to act as carriers for other molecules or to form bio‐compatible materials, present one such possibility. Although not well described, several polycations such as chitosan and polyarginine, have displayed anti‐inflammatory properties. The present work shows the ubiquitous laboratory transfection reagent, polyethylenimine (PEI) and more specifically low molecular weight branched PEI (B‐PEI) as also possessing such properties. Using a RAW264.7 murine cell line macrophage as an inflammation model, it is found the B‐PEI 700 Da as being capable of reducing the production of several pro‐inflammatory molecules induced by the endotoxin lipopolysaccharide. Although further studies are required for elucidation of its mechanisms, the revelation that such a common lab reagent may present these effects has wide‐ranging implications, as well as an abundance of possibilities.
Funder
Fondation ARC pour la Recherche sur le Cancer